Asia-Pacific Needle Biopsy Market, By Needle Type (Trephine Biopsy Needles, Klima Sternal Needle, Salah Needle Aspiration Needle, Jamshidi Needle and Others), Ergonomics (Sharp, Blunt, Quincke, Chiba, Franseen and Others), Procedure (Fine-Needle Aspiration Biopsy, Core Needle Biopsy, Vacuum-Assisted Biopsy, Image-Guided Biopsy), Sample Site (Muscles, Bones and Other Organs), Utility (Disposable and Reusable), Application (Tumour, Infection, Inflammation and Others) – Industry Trends and Forecast to 2029.
Asia-Pacific Needle Biopsy Market Analysis and Size
The needle biopsy market is expected to witness significant growth during the forecast period. The expansion of the market for needle-based biopsy is directly proportional to the incidence of cancer cases worldwide. This will increase the acceptance of needle-based biopsy, thereby advancing the market. Rapid innovation and technological advances impact the needle-based biopsy market, with ongoing product development to improve patient comfort during and after surgery and reduce trauma. This market is at utmost demand and is expected to foresee a huge growth in the forecast period.
Data Bridge Market Research analyses a growth rate in the needle biopsy market in the forecast period 2022-2029. The market was valued at USD 180 million in 2021. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Asia-Pacific Needle Biopsy Market Scope and Segmentation
2022 to 2029
2020 (Customizable to 2014 - 2019)
Revenue in USD Million, Volumes in Units, Pricing in USD
Needle Type (Trephine Biopsy Needles, Klima Sternal Needle, Salah Needle Aspiration Needle, Jamshidi Needle and Others), Ergonomics (Sharp, Blunt, Quincke, Chiba, Franseen and Others), Procedure (Fine-Needle Aspiration Biopsy, Core Needle Biopsy, Vacuum-Assisted Biopsy, Image-Guided Biopsy), Sample Site (Muscles, Bones and Other Organs), Utility (Disposable and Reusable), Application (Tumour, Infection, Inflammation and Others)
Japan, China, South Korea, India, Australia, Singapore, Thailand, Malaysia, Indonesia, Philippines, Rest of Asia-Pacific
Market Players Covered
Boston Scientific Corporation (U.S.), Hologic, Inc. (U.S.), ST. STONE MEDICAL DEVICES PVT. LTD (India), AprioMed AB (Sweden), Amecath (Egypt), Cardinal Health (U.S.), BD (U.S.), Merit Medical Systems (U.S.), Swastik Enterprise (India), B. Braun SE (Germany)
A needle biopsy is an image-guided or ultrasound procedure that is used to obtain a sample of cells from the human body for laboratory or diagnostic testing, particularly of the tumour. The common needle biopsy procedures include fine-needle aspiration biopsy and Core Needle Biopsy. A needle biopsy comes in place whenever there is an abnormal lump or when the imaging scans show abnormalities in the body. It is gaining enormous importance to physicians and doctors and is expected to have a huge growth in the forecast period.
Needle Biopsy Market Dynamics
- Increasing Cancer Cases
Incidence of cancer cases is directly helping expand the needle biopsy market globally. According to the WHO, in 2030, deaths caused because of cancer are expected to reach 13 billion worldwide. A rapid growth in the incidence of cancer across the globe is expected to increase the number of patients undergoing biopsies. This will consequently increase the adoption of needle-based biopsy guns, driving market growth.
- Increased Elderly Population
Cancer is thought to be an age-related disease, as per the researchers. According to several studies, people over the age of 50 are more prone to cervical, breast, and prostate cancer. During the projected period, this is expected to boost the market.
- Clinical Research and Reimbursement
The several advanced innovations of needle biopsy, promising clinical studies, and better reimbursement policies are expected to provide substantial growth opportunities for the needle biopsy market from 2022 to 2029.
- Advanced Technologies
Adopting technologies such as using artificial intelligence in the needle biopsy market is creating an opportunity for the growth of the same. For instance, Freenome, an AI genomics business based in the United States, announced in October 2018 that it is working on developing blood tests that utilize AI to detect the body's early-warning indications of cancer. The company released preliminary evidence in R&D in October 2018 for applying machine learning to detect colorectal cancer in its early stages.
- Lack of skilled professionals
The lack of qualified personnel who cannot use these systems could curb the growth of the Asia-Pacific needle biopsy market over a forecast period.
- High Cost
The high cost of these treatment processes can impede the growth of the needle biopsy market even though the disease incidence is high.
This Asia-Pacific needle biopsy market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the Asia-Pacific needle biopsy market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
COVID-19 Impact on Asia-Pacific Needle Biopsy Market
COVID-19 has left a major public health crisis that has impacted practically every sector, and its long-term consequences are expected to influence industry growth during the forecast period.
In the post pandemic era, there is huge expectation of surge in the needle biopsy market as cancer prevalence is independent of the current scenario. And also, as the hospitals and research insititutes have lower cases of covid-19 infection, the focus will increase again on the cancer cases.
- In January 2021, Hologic, Inc acquired SOMATEX Medical Technologies GmbH, for USD 64.00 million. This aims to deliver a range of novel solutions for breast cancer treatment. Hologic, Inc would be able to expand the breast cancer marker portfolio.
Asia-Pacific Needle Biopsy Market Scope
Asia-Pacific needle biopsy market is segmented on the basis of needle type, procedure, sample site and application. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
- Trephine Biopsy Needles
- Klima Sternal Needle
- Salah Needle Aspiration Needle
- Jamshidi Needle
- Fine-Needle Aspiration Biopsy
- Core Needle Biopsy
- Vacuum-Assisted Biopsy
- Image-Guided Biopsy
- Other Organs
Asia-Pacific Needle Biopsy Market Regional Analysis/Insights
The Asia-Pacific needle biopsy market is analyzed and market size insights and trends are provided by needle type, procedure, sample site and application as referenced above.
The major countries covered in the Asia-Pacific needle biopsy market are Japan, China, South Korea, India, Australia, Singapore, Thailand, Malaysia, Indonesia, Philippines, Rest of Asia-Pacific.
China is expected to dominate the Asia-Pacific needle biopsy market due to higher awareness regarding the treatment for cancer and favourable reimbursement scenario for needle biopsy in China.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Asia-Pacific Needle Biopsy Market Share Analysis
The Asia-Pacific needle biopsy market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to Asia-Pacific needle biopsy market.
Key players operating in the Asia-Pacific needle biopsy market include:
- Boston Scientific Corporation (U.S.)
- Hologic, Inc. (U.S.)
- ST. STONE MEDICAL DEVICES PVT. LTD (India)
- AprioMed AB (U.S.)
- Amecath (Egypt)
- Cardinal Health (U.S.)
- BD (U.S.)
- Merit Medical Systems (U.S.)
- Swastik Enterprise (India)
- B. Braun SE (Germany)